Mutational analysis of the N-ras, p53, p16(INK4a), CDK4, and MC1R genes in human congenital melanocytic naevi

Journal of Medical Genetics

Volumn 36, Issue 8, 1999, Pages 610-614

  Papp, Thilo ^a   Pemsel, Heidi ^a   Zimmermann, Regina ^a   Bastrop, Ralf ^a   Weiss, Dieter G ^a   Schiffmann, Dietmar ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

N ras; Naevi; p16; p53

Indexed keywords

ARGININE; HORMONE RECEPTOR; LYSINE; PROTEIN P16;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CODON; EXON; FEMALE; GENETIC SCREENING; HUMAN; HUMAN CELL; MALE; MELANOCYTE; MELANOCYTIC NEVUS; MISSENSE MUTATION; ONCOGENE N RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN DEFECT;

EID: 0032767677     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Schleicher SM, Lim SJ. Congenital nevi. Int J Dermatol 1995;34:825-9.
2. Sober AJ, Burstein JM. Precursors to skin cancer. Cancer 1995;75:645-50.
3. Herlyn M, Satyamoorthy K. Activated ras. Yet another player in melanoma? Am J Pathol 1996;149:883-93.
4. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994;131:72-7.
5. Jafari M, Papp T, Kirchner S, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of malignant melanoma. J Cancer Res Clin Oncol 1995;121:23-30.
6. Hesketh R. The oncogene and tumor suppressor gene factsbook. 2nd ed. New York: Academic Press, 1997.
7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
8. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
10. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
11. Papp T, Jafari M, Schiffmann D. Lack of p53 mutations and loss of heterozygosity in non-cultured melanocytic lesions. J Cancer Res Clin Oncol 1996;122:541-8.
12. Haluska FG, Hodi, FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998;16:670-82.
13. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-8.
14. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-18.
15. Guldberg P, Kirkin AF, Gronbaek K, Thor Straten P, Ahrenkiel V, Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997;72:780-3.
16. Elwood JM. Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg 1992;16:157-65.
17. Tsao H, Sober AJ. Ultraviolet radiation and malignant melanoma. Clin Dermatol 1998;16:67-73.
18. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995;62:367-76.
19. Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol 1995; 141:934-42.
20. Valverde P, Healy E, Jackson I, Rees JL Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30.
21. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-6.
22. Erlich HA. PCR technologies: principles and applications for DNA amplification. New York: Stockton Press, 1989.
23. Papp T, Pemsel H, Bastrop R, Zimmermann R, Weiss DG, Schiffmann D. Combined ASRA/SSCP analysis facilitates screening and characterization of point mutations within defined codons in cellular subpopulations. Trends Genet Tech Tips Online 1998:T01375.
24. Gruis NA, Weaver-Feldhaus J, Liu Q, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995;146:1199-206.
25. Hahn SA, Kern SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995;75:857-69.
26. Soussi T, Caron de Fromentel C, Mechali M, May P, Kress M. Cloning and characterisation of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene 1987;1:71-8.
27. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
28. Nigro JM, Baker SJ, Preisinger AC. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
29. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
30. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
31. INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harbour Symp Quant Biol 1994;LIX:0-87969-067-4/94.
32. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-12.
33. Papp T, Pemsel H, Weiss DG, Schiffmann D. Simultaneous detection of homozygous deletion and point mutations in tumor suppressor genes p16 and p53 by multiplex-PCR/ SSCP analysis. Trends Genet Tech Tips Online 1997:T01018.
34. INK4a-insensitive CDK4 mutant targeted by cytolytic T-lymphocytes in a human melanoma. Science 1995;269:1281-4.
35. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent-4 gene. Cancer Res 1998;58:109-13.
36. Epe B. DNA damage profiles induced by oxidizing agents. Rev Physiol Biochem Pharmacol 1995;127:223-49.
37. Ballmaier D, Pflaum M, Kielbassa C, Epe B. Oxidative DNA damage profiles in mammalian cells. Recent Results Cancer Res 1997;143:35-47.
38. Shibutani S, Takeshita M, Grollmann AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxoG. Nature 1991;349:431-4.
39. Moriya M, Ou C, Bodepudi V, Johnson F, Takeshita M, Grollmann AP. Site-specific mutagenesis using a gapped duplex vector: a study of translesion synthesis past 8-oxodeoxyguanosine in E coli. Mutat Res 1991;254:281-8.
40. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted GC to TA transversions in simian kidney cells. Proc Natl Acad Sci USA 1993;90:1122-6.
41. Harsanyi ZP, Post PW, Brinkmann JP, Chedekel MR, Deibel RM. Mutagenicity of melanin from human red hair. Experientia 1980;36:291-2.
42. Ranadive NS, Shirwadkar S, Persad S, Menon IA. Effects of melanin-induced free radicals on the isolated rat peritoneal mast cells. J Invest Dermatol 1986;86:303-7.
43. Jimbow K. Current update and trends in melanin pigmentation and melanin biology. Keio J Med 1995;44:9-18.
44. Thody AJ, Higgins EM, Wakamatsu K, Ito S, Burchill SA, Marks JM. Pheomelanin as well as eumelanin is present in human epidermis. J Invest Dermatol 1991;97:340-4.
45. Inazu M, Mishima Y. Detection of eumelanogenic and pheomelanogenic melanosomes in the same normal human melanocyte. J Invest Dermatol 1993;100:172-5S.
46. Jimbow K, Ishida O, Ito S, Hori Y, Witkop CJ, King RA. Combined chemical and electron microscopic studies of pheomelanosomes in human red hair. J Invest Dermatol 1983;81:506-11.
47. Koppula SV, Robbins LS, Lu D, et al. Identification of common polymorphisms in the coding sequence of the human MSH receptor (MCIR) with possible biological effects. Hum Mutat 1997;9:30-6.
48. Xu X, Thornwall M, Lundin LG, Chhajlani V. Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet 1996;14:384.
49. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun 1997;237:667-72.
50. van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883-93.
51. Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989;4:1363-74.